IOVANCE BIOTHERAPEUTICS, INC. Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss of $120.00 thousand as of 2018-09-30, per its 10-Q filed 2018-11-06.
Discontinued › Notes › Investments › Debt and Equity Securities › Debt Securities, Held-to-Maturity, Fair Value to Amortized Cost, after Allowance for Credit Loss
us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss · last filed 2018-11-06
- 2018-09-30: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $120.00K.
- 2018-06-30: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $3.00K.
- 2017-12-31: Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss $0.00.
| Period end | Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss |
|---|---|
| 2018-09-30 | $120.00K 10-Q · filed 2018-11-06 |
| 2018-06-30 | $3.00K 10-Q · filed 2018-08-07 |
| 2017-12-31 | $0.00 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |